Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Toyama, Yoichi ^a   Yoshida, Seiya ^a   Saito, Ryota ^a   Kitamura, Hiroaki ^a   Okui, Norimitsu ^a   Miyake, Ryo ^a   Ito, Ryusuke ^b   Son, Kyonsu ^a   Usuba, Teruyuki ^a   Nojiri, Takuya ^a   Yanaga, Katsuhiko ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; Bi weekly gemcitabine; Mild dose intensity; Pancreatic cancer; Patient's quality of life; QLQ C30 and QLQ PAN26; Survival prolongation

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT COMPLIANCE; POSTOPERATIVE CARE; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84872016548     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-3     Document Type: Article

References (54)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2012, 23:1044-1052. 10.1093/annonc/mds024, 22373539.
2. Bakkevold KE, Amesiø B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and pappilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993, 29A:698-703. 10.1016/S0959-8049(05)80349-1, 8471327.
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413. PMID: 9196156.
4. Lygidakis NJ, Berberabe AE, Spentzouris N, Dedemadi G, Kalligas T, Loukas G, Sotiropoulou V. A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma. Hepatogastroenterology 1998, 45:2376-2381.
5. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-784. 10.1097/00000658-199912000-00006, 1420941, 10615932.
6. Kachnic LA, Shaw JE, Manning MA, Lauve AD, Neifeld JP. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int J Cancer 2001, 96:132-139. 10.1002/ijc.1008, 11291097.
7. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW, . European Study Group for Pancreatic Cancer Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585. 10.1016/S0140-6736(01)06651-X, 11716884, European Study Group for Pancreatic Cancer.
8. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW, . European Study Group for Pancreatic Cancer A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl J Med 2004, 350:1200-1210. 10.1056/NEJMoa032295, 15028824, European Study Group for Pancreatic Cancer.
9. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Büchler MW, Neoptolemos JP, . Pancreatic Cancer Meta-Analysis Group Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008, 143:75-83. 10.1001/archsurg.2007.17, 18209156, Pancreatic Cancer Meta-Analysis Group.
10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F, . European Organization for Research and Treatment of Cancer Study Group on Quality of Life The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390, European Organization for Research and Treatment of Cancer Study Group on Quality of Life.
11. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Büchler MW, Dervenis C, Fernandez Cruz L, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T, . EORC Study Group on Quality of Life Development of a disease specific quality of life (QOL) questionnaire module to supplement the EORTC core cancer QOL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 1999, 35:939-941. 10.1016/S0959-8049(99)00047-7 [PMID: 10533475], 10533475, EORC Study Group on Quality of Life.
12. Czakó L, Takács T, Hegyi P, Prónai L, Tulassay Z, Lakner L, Döbrönte Z, Boda K, Lonovics J. Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis. Can J Gastroenterol 2003, 17:597-603.
13. McClaine RJ, Lowy AM, Matthews JB, Schmulewitz N, Sussman JJ, Ingraham AM, Ahmad SA. A comparison of pancreaticoduodenectomy and duodenum-preserving head resection for the treatment of chronic pancreatitis. HPB 2009, 11:677-683. 10.1111/j.1477-2574.2009.00118.x, 2799621, 20495636.
14. Sobin LH, Wittekind C. UICC, International Union against Cancer; TNM Classification of Malignant Tumours 2002, 93-96. New York: Wiley-Liss, 6.
15. Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP, . Pancreatic Cancer Meta-analysis Group Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92:1372-1381. 10.1038/sj.bjc.6602513, 2361989, 15812554, Pancreatic Cancer Meta-analysis Group.
16. Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(vl) trials. Br J Cancer 2009, 100:246-250. 10.1038/sj.bjc.6604838 [PMID: 19127260], 2625958, 19127260.
17. Van Laethem JL, Demols A, Gay F, Closon MT, Collette M, Polus M, Houbiers G, Gastelblum P, Gelin M, Houtte PV, Closset J. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiation Oncology Biol Phys 2003, 56:974-980.
18. Kurosaki I, Hatakeyama K. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer. Hepatogastroenterology 2004, 51:634-637.
19. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, Tepper JE. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006, 95:260-265. 10.1038/sj.bjc.6603270, 2360633, 16868545.
20. Cantore M, Serio G, Pederzoli P, Mambrini A, Iacono C, Pulica C, Capelli P, Lombardi M, Torri T, Pacetti P, Pagani M, Fiorentini G. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2006, 58:504-508. 10.1007/s00280-006-0200-2, 16633830.
21. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakagawa N, Ohge H, Sueda T. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg 2008, 195:757-762. 10.1016/j.amjsurg.2007.04.018, 18367131.
22. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg 2009, 13:85-92. 10.1007/s11605-008-0650-4, 18704593.
23. You DD, Lee HG, Heo JS, Choi SH, Choi DW. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2009, 13:1699-1706. 10.1007/s11605-009-0969-5, 19582512.
24. Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Doh J, Yamato I, Hokuto D, Nishiofuku H, Marugami N, Kanehiro H, Kichikawa K, Nakajima Y. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci 2011, 18:235-239. 10.1007/s00534-010-0336-7, 21165654.
25. Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol 2011, 18:1122-1129. 10.1245/s10434-010-1401-9, 21104328.
26. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - a randomized controlled trial. JAMA 2007, 297:267-277. 10.1001/jama.297.3.267, 17227978.
27. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - a randomized controlled trial. JAMA 2008, 299:1019-1026. 10.1001/jama.299.9.1019, 18319412.
28. Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011, 18:1319-1326. 10.1007/s00280-012-1822-1, 21499862.
29. Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H, Otsuka M, Kato A, Nozawa S, Furukawa K, Miyazaki M, . Pancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital Group A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008, 113:2448-2456. 10.1002/cncr.23863, 18823024, Pancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital Group.
30. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 2009, 101:908-915. 10.1038/sj.bjc.6605256, 2743365, 19690548.
31. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M, Collette L, Budach V, Lutz M, Van Cutsem E, Haustermans K. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010, 28:4450-4456. 10.1200/JCO.2010.30.3446, 2988636, 20837948.
32. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, . European Study Group for Pancreatic Cancer Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012, 308:147-156. 10.1001/jama.2012.7352, 22782416, European Study Group for Pancreatic Cancer.
33. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T, . Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? - a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95:1685-1695. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract.
34. Kosuge T, Kiuchi T, Mukai K, Kakizoe T, . Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP) A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006, 36:159-165. 10.1093/jjco/hyi234, 16490736, Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP).
35. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, . Swiss Group for Clinical Cancer Research, Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. J Clin Oncol 2007, 25:2212-2217. 10.1200/JCO.2006.09.0886, 17538165, Swiss Group for Clinical Cancer Research, Central European Cooperative Oncology Group.
36. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, . National Cancer Institute of Canada Clinical Trials Group Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677, National Cancer Institute of Canada Clinical Trials Group.
37. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513-5518. 10.1200/JCO.2009.24.2446, 19858379.
38. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: radiation therapy oncology group RTOG 0411. J Clin Oncol 2009, 27:4096-4102. 10.1200/JCO.2009.21.8529, 2734421, 19636002.
39. Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L, Stillhart P, Pestalozzi B, Herrmann R. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 2010, 21:2390-2395. 10.1093/annonc/mdq242, 20444846.
40. Okusaka T, Furuse J, Funakoshi A, Ioka T, Yamao K, Ohkawa S, Boku N, Komatsu Y, Nakamori S, Iguchi H, Ito T, Nakagawa K, Nakachi K. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 2011, 102:425-431. 10.1111/j.1349-7006.2010.01810.x, 21175992.
41. Feliu J, Borrega P, León A, López-Gómez L, López M, Castro J, Belda-Iniesta C, Barriuso J, Martínez V, González-Barón M. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemother Pharmacol 2011, 67:215-221. 10.1007/s00280-010-1472-0, 20927525.
42. Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, Kawahara H, Watanabe M, Toyama Y, Yanagisawa S, Kobayashi S, Yanaga K, Fujise K, Gong J, Tajiri H. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 2007, 179:4874-4883.
43. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2009, 39:797-806. 10.1093/jjco/hyp112, 19797418.
44. Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, Skaar T, De Petris G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009, 182:216-224.
45. Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon AH, Komatsu N, Itoh K, Noguchi M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010, 24:795-801.
46. Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011, 34:92-99. 10.1097/CJI.0b013e3181fb65b9, 21150717.
47. Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M, Uesaka K. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01). Jpn J Clin Oncol 2008, 38:227-229. 10.1093/jjco/hym178, 18272475.
48. Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 2012, 69:1197-1204. 10.1007/s00280-012-1822-1, 22249272.
49. Thomas A, Dajani K, Neoptolemos JP, Ghaneh P. Adjuvant therapy in pancreatic cancer. Dig Dis 2010, 28:684-692. 10.1159/000320099, 21088421.
50. Holzman DC. Pancreatic cancer: will incremental advances begin to make a difference?. J Nat Cancer Inst 2010, 102:1821-1823. 10.1093/jnci/djq521, 21139096.
51. Richter J, Saif MW. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond - highlights from the '2010 ASCO gastrointestinal cancers symposium'. Orlando, FL, USA. January 22-24, 2010. JOP 2010, 11:144-147.
52. Brus C, Saif MW. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? - highlights from the '2010 ASCO annual meeting'. Chicago, IL, USA. June 4-8, 2010. JOP 2010, 11:321-323.
53. O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma: where are we going?. Expert Rev Anticancer Ther 2011, 11:173-177. 10.1586/era.10.232, 21342036.
54. Saif MW. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011. JOP 2011, 12:106-109. PMID: 21386631.